adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant MTC who require systemic therapyadult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion–positive thyroid carcinoma who require systemic therapy and who are radioactive iodine-refractory. The gene discussed is RET; the disease is thyroid gland carcinoma.